Background:  Meningitis and pneumonia caused by Streptococcus pneumonia are serious overwhelming infections nowadays in Egypt. Immunity is long lasting. Mortality rate of pneumococcal pneumonia occurs annually worldwide was estimated to be about 10% despite antimicrobial treatment. Ahigher mortality rate was found in patients with pneumococcal bacteremia, as it reached approximately 25 in the past forty years. Objectives: Development of lipid nanoparticles(LNP)- RNA vaccine against Streptococcus pneumonia gene cluster facilitating the synthesis of the capsular polysaccharide in Egypt. Methodology: In the present screening experimental study, LNP-mRNA vaccine against Streptococcus pneumonia gene cluster facilitating the synthesis of the capsular polysaccharide could be produced. The lipid nanoparticle vaccine delivery system size was 85 nm. Immunogenicity was assessed in animal testing stages; then, during clinical trials phases 1/2. Results: The vaccine showed 91% efficacy during animal testing while it was 88% in clinical trials stages 1/2. It showed superior biological activity and fewer side effects than other standard vaccines. The efficacy was long lasting due to production of powerful neutralizing antibodies against gene cluster proteins facilitating the synthesis of the capsular polysaccharide of 23 serotypes of Streptococcus pneumonia. Conclusion: The vaccine, in our study was effective as prophylaxis against that bacterial infection. It needs to be updated periodically to overcome the problem of high mutation rate.